Compare Gold Fields Limited (GFI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs BIO-TECHNE Corp — how do they compare? Gold Fields Limited trades at $36.7 (market cap $31.26B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Gold Fields Limited is far larger — about 2.7× BIO-TECHNE Corp's market cap, and Gold Fields Limited pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and BIO-TECHNE Corp for 63 Days on average.
| GFI | TECH | |
|---|---|---|
Market Cap | $31.26B | $11.37B |
Volume | 3,397,922 | 3,153,511 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $72.61 |
52-Week Low | $31.25 | $43.31 |
Typical Hold Time | 49 Days | 63 Days |
Enterprise Value | $31.87B | $11.40B |
Dividend Yield | 6.14% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.86, down 0.86% with bearish technical signals but strong fundamentals including 40.76% net margin and 58.38% ROE. Recent earnings show mixed results with one beat and three misses against expectations. The company's proposed $27 billion takeover of Northern Star was rejected, creating near-term uncertainty while highlighting growth ambitions. Operating cash flow surged to $3.77 billion in 2025, supporting robust shareholder returns.
GFI presents a value opportunity with low P/E of 7.14 and 44% upside to consensus target of $52.75, though recent acquisition volatility and earnings misses warrant caution. The stock's bearish technical posture contrasts with strong cash generation and analyst support (8 Buy, 10 Hold ratings), creating potential for recovery as standalone operations deliver growth.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
